spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Immunomedics 

 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Aug 2015
Immunomedics Appoints Arthur S. Kirsch as Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2011
Immunomedics Creates Targeted Therapeutics for Solid Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2011
Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2010
Brian Markison to Join Rosetta Genomics Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 16 Jun 2010
New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2010
Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2010
Immunomedics Appoints Kenneth J. Zuerblis to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2009
Immunomedics' hPAM4 Labeled With Yttrium-90 Receives Fast Track Designation From FDA for Therapy of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2007
Pacira Pharmaceuticals Names David M. Stack CEO and President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Urigen Pharmaceuticals, Inc. Appoints Cynthia L. Sullivan and Robert J. Watkins to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Aug 2007
Immunomedics Appoints Edward T. Wolynic to Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2007
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2006
FDA Allows Resumption of Lupus Trials with Epratuzumab
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2006
Repeated Radioimmunotherapy With 131I-Labetuzumab in Colorectal Cancer With Liver Metastases Found Safe and Well-Tolerated in Initial Phase II Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
Immunomedics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.